Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when MOTS-c crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 506 certificate records for MOTS-c products, from 110 vendors 351 reference a report on the testing laboratory's own system · 254 have a laboratory lookup that answered when last checked · 482 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Anti-aging / mitochondrial research

Primary research area: Anti-aging. Also surfaces under Weight loss for browsing and discovery.

Body systems

Systemic · Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases

MOTS-c Peptide

Signal depth

Medium

No FDA label signal · 8 trials · 264 PubMed results

Promising

Research evidence

MOTS-c has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

MOTS-c has 3 name-matched clinical trials (highest phase: Phase 2) and 264 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet. Note: 1 retracted publication in the literature.

⚠ 1 retracted publication

Human data

Phase 2

Trial quality

Randomized

Outcomes

Clinical outcomes

Replication

Multiple trials

Literature

Top-tier journals

PHASE2 · Randomized MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity Trial Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD NA · Randomized Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation Cell Metabolism · 721 citations The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance Cell Metabolism · 311 citations The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress Nature Communications · 209 citations MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-07 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What MOTS-c is

MOTS-c is a mitochondria-derived peptide that appears in metabolic-health, exercise-response, and longevity-oriented research discussions.

Why it matters

It is one of the most recognizable names in the peptide-longevity crossover category and shows how anti-aging marketing often borrows from metabolic research.

Regulatory context

MOTS-c is not FDA approved in the United States and is best understood as a research-market profile.

Practical reading note

The most useful way to read MOTS-c is as a research-interest compound, not as an established anti-aging intervention.